Gamma secretase plays a role in the production of beta-amyloid, a major component of plaque in the brain, which is thought to be a cause of Alzheimer’s disease.
E2012 is a new chemical entity discovered by Eisai and, in preclinical research, has shown some potential to reduce the production of beta-amyloid by modulating the function of gamma secretase. E2012 and its effect on beta-amyloid will now be evaluated in people.
“As a leader in Alzheimer’s disease therapy, in part through its marketed drug, Aricept, Eisai is pursuing a multi-faceted approach to Alzheimer’s disease research that includes investigating genes responsible for the onset of the disease, immunotherapy and vaccine therapy,” said the company in a statement.